/ /

Ophthalmology

Targeted vitreoretinal lymphoma therapies mimic other approaches
Targeted vitreoretinal lymphoma therapies mimic other approachesVitreoretinal lymphomas are both deceptive and deadly. While there are only about 350 cases reported annually in the United States, median survival is less than 5 years, said Rajesh C. Rao, MD.
Tapping gene therapy potential for inherited retinal diseases
Tapping gene therapy potential for inherited retinal diseasesThe gene therapy technology already exists to treat most inherited retinal disease. The current challenge is to drive down the costs of implementing the technology.
Aspiring for zero tolerance of residual astigmatism
Aspiring for zero tolerance of residual astigmatismWhen considering premium surgeries and high expectations from patients along with an unrelenting quest for vision exceeding 20/20, the tolerance of residual astigmatism must be zero. Like bespoke tailors, ophthalmologists need to be bespoke surgeons who tailor vision in each eye to the highest level possible. We cannot claim to design the best suit using the best technology and tailoring materials, and yet, in our minds, find it “acceptable” to have the suit length within a half-inch to three-quarters of an inch too short or wide.
Sulcus refractive IOLs solid option for presbyopia, other refractive errorsImplantation of a sulcus-supported, pseudophakic supplementary intraocular lens (IOL) can be a safe and effective method for improving vision in eyes with residual refractive error after cataract extraction, refractive lens exchange, or keratoplasty, said Thomas Kohnen, MD, PhD. It also can be used to provide reversible presbyopia correction.
Dislocation main reason for IOL explantations, survey findsThe most common complication associated with the explantation of foldable intraocular lenses (IOLs) is lens dislocation or decentration. While glare and visual aberrations are the most common reasons for explanting multifocal lenses.
FDA approves tocilizumab, first therapy for GCA
FDA approves tocilizumab, first therapy for GCAThe FDA recently granted regulatory approval for tocilizumab (Actemra, Genentech), the first approved therapy for the treatment of adults with giant cell arteritis.
Retirement is around the corner for David Karcher, ASCRS executive director
Retirement is around the corner for David Karcher, ASCRS executive directorDavid Karcher, executive director and chief executive officer, The American Society of Cataract and Refractive Surgery (ASCRS), will retire as of December 31, 2018, according to an ASCRS press release. Eric D. Donnenfeld, MD, will chair the search committee responsible for interviewing candidates to fill the role of executive director. Interviews will begin in the late summer or early fall of 2017. Leonard Pfeiffer & Company, a well-known executive search firm, will be assisting in the search.
Pros and cons of compounded pharmaceuticalsCompounded pharmaceuticals have been used for decades, but does that mean they are reliable and safe? “Absolutely,” asserted Dante Pieramici, MD. “The literature disagrees,” said Julia Haller, MD.
New and different therapies emerging through uveitis pipelineLocal therapy plays a significant role in the treatment of uveitis, either as monotherapy or in combination therapy. Alongside a number of pharmacotherapeutic agents, new products and technologies are in development that could expand clinicians’ options and improve outcomes.
Endoillumination growth amplifies tissue visualizationEndoillumination for vitreoretinal surgery continues to improve with the introduction of brighter, safer light sources with color filters that may allow opportunities for better tissue visualization.